Description

Lenacapavir is a next-generation antiviral inhibitor targeting HIV capsid assembly and core formation. It provides a novel mechanism of action for HIV research by binding capsid protein and disrupting viral replication. This injectable formulation is designed for use in laboratory research exploring HIV lifecycle, capsid-targeting strategies, and antiviral resistance profiling.

Each box contains two 1.5ml sterile vials delivering 0.4635g Lenacapavir per vial. Manufactured by Patheon Italia S.p.A., and NMPA-approved (HJ20240170). This formulation is strictly for nonclinical investigative use in immunology and virology research models.

Product Specifications

Mechanism of Action & Research Applications

Lenacapavir specifically binds to the HIV capsid protein, disrupting capsid assembly and viral core formation. It inhibits early and late stages of viral replication, making it a valuable tool for:

• HIV capsid-binding antiviral research

• Capsid-driven viral assembly studies

• Resistance profiling of novel antiretroviral agents

• Pharmacodynamics and pharmacokinetics of capsid inhibitors

This product supports basic and translational HIV research focusing on novel mechanisms of viral inhibition.

Side Effects (For Reference Only in Models)

In controlled experimental models, Lenacapavir Injectable may exhibit:

• Altered viral replication kinetics

• Cytotoxic effects at very high doses in cell culture

• Possible cytostatic actions in host cell lines

These observations are context-specific and not clinical safety data.

Disclaimer

Lenacapavir Injection (SUNLENCA) is intended for laboratory research use only and is not approved for therapeutic, diagnostic, or veterinary use. Users must adhere to institutional and regulatory safety protocols.